The EU campaign to vaccinate Europeans against Covid-19 got off to an uneven start in what will be a marathon effort to administer shots to enough of the bloc’s 450 million people to defeat the viral pandemic.

The United Kingdom, which was the first to grant authorization to the vaccine developed by Pfizer and Moderna, is expected to give the green light to the vaccine developed by AstraZeneca and Oxford University this week.

Novavax Inc. started a large late-stage study of the company’s experimental Covid-19 vaccine in the United States after delaying the trial twice due to issues in scaling up the manufacturing process.

Europe launched a mass Covid-19 vaccination drive on Dec. 27 with pensioners and medics lining up to get the first shots to see off a pandemic that has crippled economies and claimed more than 1.7 million lives worldwide.

AstraZeneca and Amgen said their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients’ dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.

Swiss drugmaker Roche’s experimental eye medicine faricimab matched Bayer and Regeneron’s Eylea against diabetic macular degeneration in acuity gains in two studies, including one in which patients had less-frequent shots.

The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices voted to recommend the use of Moderna Inc.’s Covid-19 vaccine on people 18 years of age and older.

U.S. Vice President Mike Pence received his Covid-19 vaccine live on television on Dec. 18, seeking to shore up public support for vaccinations after U.S. deaths from the coronavirus topped 3,000 for a third straight day.

Biogen Inc. agreed to pay $22 million to resolve U.S. allegations that the company illegally used two charities that help cover Medicare patients’ out-of-pocket drug costs as a means to pay them kickbacks to use the Cambridge, Mass-based drugmaker’s multiple sclerosis medicines.

U.S. coronavirus deaths soared to a daily record of 3,580 and hospitalizations rose for the 19th straight day on Dec. 16, ramping up the stakes as regulators on Dec. 17 considered whether to approve a second Covid-19 vaccine.